Loading...

OmniAb, Inc.

OABIWNASDAQ
Healthcare
Biotechnology
$0.24
$0.03(13.56%)

OmniAb, Inc. (OABIW) Company Profile & Overview

Explore OmniAb, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

OmniAb, Inc. (OABIW) Company Profile & Overview

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

SectorHealthcare
IndustryBiotechnology
CEOMr. Matthew W. Foehr

Contact Information

510 250 7800
5980 Horton Street, EmeryVille, CA, 94608

Company Facts

114 Employees
CountryUS
Actively Trading

Frequently Asked Questions